Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus KARBINAL ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus KARBINAL ER.
DRIXORAL vs KARBINAL ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Carbinoxamine is a first-generation antihistamine with anticholinergic and sedative properties. It competitively antagonizes histamine at H1 receptor sites, thereby alleviating symptoms of allergic reactions.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
Adults: 1-2 tablets (6-12 mg carbinoxamine) orally every 4-6 hours as needed; maximum 24 mg/day.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Terminal elimination half-life ranges from 20 to 30 hours, supporting once-daily dosing in extended-release formulation.
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Renal (approximately 50% as unchanged drug and metabolites); fecal (approximately 40%); biliary (minor).
Category C
Category C
Antihistamine/Decongestant
Antihistamine